A Study of RO5036505 in Patients With Moderate to Severe Asthma
Status:
Withdrawn
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety
and tolerability of RO5036505 in patients with inadequately controlled moderate to severe
asthma. Patients will be randomized to receive either RO5036505 (380mg iv infusion once
weekly) or placebo for 8 weeks. Patients will be on a standardized inhaled
corticosteroid/long-acting beta-agonist regimen during study treatment. Target sample size is
50-100 individuals.